Physician profile
Ronald Cucina
NPI 1396738886
$1,845.17
in general payments reported to CMS, 2019-2025
27 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $171 · 2021: $322 · 2022: $179 · 2023: $346 · 2024: $240 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.07 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.24 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $356.92 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $145.05 | 2023-2025 | Gemtesa, Myfembree |
| Lupin INC. | $109.95 | 2019-2020 | |
| Novo Nordisk INC | $88.96 | 2021-2024 | Wegovy |
| Pfizer INC. | $88.30 | 2019-2025 | |
| Organon LLC | $76.47 | 2021-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $72.76 | 2019-2025 | |
| Hologic Sales and Service, LLC | $67.79 | 2021-2023 | Aptima, Acessa Provu System |
| Roche Diagnostics Corporation | $66.88 | 2019-2021 | |
| Biogen, INC. | $41.93 | 2024-2025 | Zurzuvae |
| Minerva Surgical, INC | $30.59 | 2021 | |
| Merck Sharp & Dohme LLC | $28.60 | 2019-2020 | |
| Cgg Medical INC | $27.88 | 2025 | |
| Aspira Women'S Health INC | $27.48 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $24.94 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Mycovia Pharmaceuticals, INC. | $24.72 | 2023 | Vivjoa |
| Exeltis, USA INC. | $24.68 | 2022 | |
| Sanara Medtech INC. | $20.44 | 2025 | Celleraterx |
| Eisai INC. | $18.45 | 2021 | |
| Kvk-Tech, INC. | $17.88 | 2019 | |
| Baxter Healthcare | $15.96 | 2022 | |
| Lilly USA, LLC | $14.50 | 2024 | Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $13.89 | 2022 | |
| Shield Therapeutics INC | $13.09 | 2024 | |
| Allergan, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Cucina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.